MedPath

Randomized, open-label, single dose, four-period, cross-over drug-drug interaction study comparing reference products Crestor 20 mg film coated tablets, Norvasc 10 mg tablets and Tritace 10 mg tablets administrated concomitantly versus each drug administrated alone in healthy male and female subjects under fasting conditions.

Phase 1
Conditions
ot applicable (submitted trial is a study in healthy subjects).
MedDRA version: 20.0Level: PTClassification code: 10020772Term: Hypertension Class: 100000004866
Therapeutic area: Diseases [C] - Cardiovascular Diseases [C14]
Registration Number
CTIS2023-505153-41-00
Lead Sponsor
Adamed Pharma S.A.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
ot Recruiting
Sex
All
Target Recruitment
60
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
Interventional clinical trial of medicinal product
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Main Objective: ;Secondary Objective: ;Primary end point(s):
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath